Design: Cell viability, ACTH secretion (enzyme-linked immunosorbent assay), apoptosis, and gene expression profile were investigated on AtT-20 cells. In vivo efficacy was examined in an athymic nude mouse AtT-20 xenograft model. SAHA efficacy against human-derived corticotroph tumor (hCtT) (n = 8) was tested in vitro.
C ushing disease (CD) is characterized by a state of hypercortisolism driven by an adrenocorticotropin hormone (ACTH)-secreting adenoma and is associated with twoto fivefold increased mortality (1, 2) . Although curative treatments return mortality risk to baseline, substantial morbidity persists (1, 3) . Successful resection of a CDassociated pituitary adenoma can lead to immediate and lasting biochemical remission in 80% to 90% of patients (1, (3) (4) (5) . Consequently, transsphenoidal surgery is considered the initial preferred intervention in the treatment of CD.
Remission failure from pituitary corticotroph tumors (CtTs) following transsphenoidal surgery for CD remains clinically challenging. Definitive therapy for recurrent and unremitting CD is limited to radiation and medical/surgical adrenalectomy (4) . Medical therapy, including ketoconazole and surgical adrenalectomy, offer good control of hypercortisolemia; however, these therapies come with a major burden of adverse effects. Moreover, pharmacotherapies (comprising cabergoline and pasireotide) aimed at the adenohypophysis remain mostly ineffective (6, 7) . The antitumor agent retinoic acid targets the underlying CtTs (8) but has limited effectiveness in the clinical setting (9, 10) .
Histone deacetylase inhibitors (HDACis) are compounds with promising antineoplastic properties that have generated growing interest for the treatment of different types of cancers (11, 12) . Suberoylanilide hydroxamic acid (SAHA; Vorinostat) is an oral pan-HDACi approved by the Food and Drug Administration (FDA) that has induced growth arrest and increased cell death in pituitary adenoma-derived cells using clinically achievable concentrations (13) . Nonetheless, the effects of HDACi on ACTHsecreting adenomas and thus the potential for biochemical remission have remained unexplored. We investigated the effect of HDACis on survival, ACTH release, and gene expression in murine and human ACTH-producing tumors.
This study demonstrated that SAHA reduced survival and ACTH release from ACTH-secreting tumor (AtT-20) and human-derived corticotroph tumor (hCtT) cells. We showed that this effect was mediated by transcriptional downregulation of pro-opiomelanocortin (POMC) via suppression of the nuclear liver X receptor alpha (LXRa). Further, we showed that SAHA differentially regulated LXRa in tumors and normal murine corticotrophs. We hypothesized that the differential regulation of LXRa may underlie the selective effect of SAHA on ACTH secretion limited to CtTs but not normal corticotrophs. These findings support the potential use of SAHA in the management of recurrent/unremitting CD.
Material and Methods

Cell culture and tissue sample collection
AtT-20/D16/16 murine CtT cells (a generous gift from Dr. Steven L. Sabol at the National Heart, Lung and Blood Institute) were cultured in T75 flasks with Dulbecco's modified Eagle medium (Gibco), 10% fetal bovine serum (Gibco, Gaithersburg, MD), and 100 U/mL of penicillin-streptomycin (Invitrogen, Carlsbad, CA) in 5% CO 2 /95% air atmosphere at 37°C. Fresh (,30 minutes posteuthanasia) mouse pituitary cells were digested and homogenized with collagenase (Sigma, St. Louis, MO; 1 mg/mL) for 30 minutes and cultured as previously described. All animal studies were approved by the Institutional Animal Care and Use Committee of the National Institutes of Health (NIH). Human pituitary tumor tissues were obtained from eight nonconsecutive patients who underwent transsphenoidal surgery for CD at the NIH from 2013 to 2016 under a protocol (NIH 03-N-0164, NCT00060541) approved by the Combined Neuroscience Institutional Review Board of the National Institute of Neurological Disorders and Stroke at the NIH. Written informed consent was obtained from each patient for research study participation, and the study was conducted according to the standards set by the institutional review board.
Animal studies
NCRNU-F sp/sp nude mice (females, aged 6 to 8 weeks; Taconic Biosciences, Hudson, NY) were randomized to five groups of five mice each: (1) saline-without tumor; (2) SAHA 25 mg/kg without tumor; (3) SAHA 25 mg/kg with tumor; (4) SAHA 50 mg/kg with tumor; and (5) saline with tumor. Animals in the tumor groups received subcutaneous injections of AtT-20 cells as described previously (14) . Treatment with intraperitoneal SAHA or saline was initiated (day zero) when xenografts reached a minimum size of 0.5 6 0.1 cm. Thereafter, tumor volume was calculated from the following formula: tumor volume = length 3 width 2 3 p/6. After 7-day treatment, facial vein blood samples were collected for ACTH analysis, and tumors and skin were collected for histological examination.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay After exposure to different concentrations of HDACi, including SAHA (0.5 mM, 1.0 mM, and 4.0 mM) for 3 to 72 hours and valproate (4 mM) and panobinostat (200 nM) for 24 hours, the cell proliferation and metabolic activity of AtT-20/D16/16 cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as reported (15) .
Fluorescence-activated sorting of murine corticotrophs and detection of apoptosis
Following dissociation and culture of pooled mouse pituitary cells (16) , corticotrophs (murine normal pituitary corticotrophs) were isolated by flow cytometry using anti-corticotropinreleasing hormone receptor 1 antibody (Invitrogen) followed by Alexa Fluor-555 conjugated antibody (Thermo Fisher, Waltham, MA). For detection of apoptosis, AtT-20 cells were exposed to SAHA (0.5 mM, 1.0 mM, and 4.0 mM) for 24 hours and then treated with Hoechst blue (Thermo Fisher) for 30 minutes followed by propidium iodide (Thermo Fisher) for 5 minutes. Lastly, cell sorting and analysis were carried out using a MoFlo Astrios cell sorter and Summit acquisition and analysis software (Beckman Coulter, Brea, CA).
RNA extraction and quantitative real-time polymerase chain reaction
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany) following manufacturer's instructions, and synthesis of complementary DNA was performed using the SuperScript III First-Strand Synthesis SuperMix kit (Invitrogen). Quantitative real-time transcription polymerase chain reaction (qRT-PCR) was performed with the CXF384 Real-Time System (Bio-Rad, Hercules, CA) and SYBR Green master mix (Applied Biosystems, Foster City, CA). Gene expression was quantified with the CFX384 Real-time System (Bio-Rad) (see Supplemental Table 1 for primer sets).
Western blot and protein complex immunoprecipitation
For protein extraction, whole-cell lysates were collected in radioimmunoprecipitation buffer containing a protease inhibitor cocktail. Proteins were electrophoretically separated on 4% to 12% Bis-Tris gels (Invitrogen) and subsequently electroblotted onto polyvinylidene difluoride membranes with the Trans-Blot Transfer Turbo System (Bio-Rad). Following blocking, membranes were probed with anti-LXRa (Abcam, UK), anti-retinoid X receptor a (RXRa; Invitrogen), anti-poly (adenosine 5 0 -diphosphate-ribose) polymerase (PARP; Cell Signaling, Danvers, MA). Immunoreactive signal was detected with the ChemiDoc MP Imaging System (Bio-Rad), and densitometric analysis was performed using Image Laboratory Software (Bio-Rad). Protein complex immunoprecipitation was performed on AtT-20 cells with anti-LXRa (Invitrogen) and anti-RXRa (Abcam, UK). Immunoprecipitates were fractionated, transferred to polyvinylidene difluoridemembranes, and immunoblotted as described previously.
ACTH enzyme-linked immunosorbent assay analysis
ACTH concentrations in CtT cells were determined by enzyme-linked immunosorbent assay (ELISA). Measurements of ACTH were performed with ACTH ELISA kits (MD Bioproducts, Hercules, CA) according to the manufacturer's instructions.
Luciferase POMC reporter assays
AtT-20/D16/16 cells (1 3 10 5 ) were placed on 24-well plates with Dulbecco's modified Eagle medium growth medium containing serum without antibiotics until a 70% to 80% confluency was reached. POMC gene reporter assays were subsequently performed with a POMC Gene Promoter Reporter Vector Kit (Affymetrix, Santa Clara, CA) as recommended by the manufacturer. Once transfection was performed, cells were exposed to different concentrations of SAHA for 3 hours. Subsequently, lysis buffer (Luciferase Assay System; Promega, Madison, WI) was added, and lysates were mixed with Luciferase Assay Reagent (Promega) and incubated for 10 minutes at room temperature. Spectrophotometric analysis was carried out with the IVIS Lumina II Imaging System (PerkinElmer, Waltham, MA).
Gene expression microarray analysis
Following SAHA exposure, whole-genome microarray analysis on the murine AtT-20/D16/16 cell line was performed with the Agilent Array platform. Sample preparation and microarray hybridization were performed according to the manufacturer's standard protocols Briefly, total RNA from each sample was amplified and transcribed into fluorescent complementary RNA using Agilent's Quick Amp Labeling protocol (version 5.7; Agilent Technologies, Santa Clara, CA). Labeled complementary RNA was hybridized onto a Whole Mouse Genome Oligo microarray (4 3 44K; Agilent Technologies). Arrays were then scanned by the Agilent Scanner G2505C, and Agilent Feature Extraction software (v11.0.1.1) was used to analyze the acquired images.
Statistical analyses
Following normalization of the raw microarray data, an unpaired t test comparison between control and experimental samples was performed using GeneSpring GX v12.1 software (Agilent Technologies). Differentially expressed genes (DEGs) with a P value #0.05 and fold-change $1.5 were selected for subsequent functional analysis.
Statistical significance was determined by one-factor analysis of variance (ANOVA) using the GraphPad Prism v6.0 software program (GraphPad, La Jolla, CA) for in vitro and in vivo results. A P value #0.05 was used to determine statistical significance.
Functional analyses
The list of DEGs that reached the preselected statistical threshold (P # 0.05 and fold-change $1.5) was further examined by the Gene Functional Classification tool in the Database for Annotation, Visualization and Integrated Discovery (v6.8) (17, 18) . Functional clusters of DEGs were calculated by the modified Fisher exact test [Expression Analysis Systematic Explorer (EASE score)], with a score of zero being the highest enrichment achievable. Biological functions that were significantly enriched (based on EASE scores) were further analyzed using the Search Tool for the Retrieval of Interacting Genes/ Proteins (STRING) database (v10.0) (19) to assess any functional association between DEG products and our proteins of interest. Identified associations with high confidence scores were further investigated.
Results
SAHA reduced AtT-20 cell line survival by inducing apoptosis
Clinically achievable concentrations of SAHA (0.5 to 4 mM) significantly reduced the viability of AtT-20 cells in concentration and time-dependent manners following a 3-to 72-hour treatment, as assessed by MTT. When compared with that of the control group, the lowest tested concentration of SAHA (0.5 mM) reduced AtT-20 survival to 60% 6 3.6% at 48 hours (ANOVA P = 0.002) [ Fig. 1(a) ]. SAHA (1 mM) reduced AtT-20 survival to 44% 6 0.3% at 48 hours (ANOVA P = 0.002) and 47% 6 1.7% at 72 hours (ANOVA P = 0.002) [ Fig. 1(a) ]. Similarly, maximal concentration of SAHA (4 mM) reduced AtT-20 cellular viability to 66% 6 1.7% at 24 hours (ANOVA P = 0.002), 21% 6 1.7% at 48 hours (ANOVA P = 0.002), and 18% 6 1.1% at 72 hours (ANOVA P = 0.002) vs control [ Fig. 1(a) ]. Subsequently, we assessed the efficacy of two additional HDACis, valproate and panobinostat, which have been recognized as useful therapeutic agents for a broad range of central nervous system disorders (20) . In our study, however, valproate (4 mM) did not reduce AtT-20 cell survival at 24 hours (Supplemental Fig. 1A) , supporting prior clinical experience (21) .
MTT measures mitochondrial activity but cannot differentiate between a reduction in cellular proliferation and/or an increase in cell death. Consistent with known proapoptotic effects in other pituitary-derived cells (13) , SAHA (1 to 4 mM) resulted in an increase of Bax/Bcl2 ratio at 24 hours [ Fig. 1(e) ]. Immunoblotting revealed an increase in cleaved PARP, a hallmark of apoptotic cell death, when AtT-20 cells were exposed to SAHA (1 to 4 mM) [ Fig. 1(d) ].
SAHA reduced secreted ACTH and POMC transcription in AtT-20 cells
Unexpectedly, within 3 hours of exposure to SAHA, doses of 0.5 mM, 1 mM, and 4 mM reduced levels of ACTH secretion by AtT-20 cells (60% 6 0.4%, 54% 6 1.9%, and 42% 6 0.4%, respectively; ANOVA P = 0.04) compared with the control group [ Fig. 2(b) ]. This effect of SAHA on ACTH in media continued at 24 hours (73% 6 7.5% [0.5 mM], 73% 6 5% [1 mM], 51% 6 5.3% [4 mM]; ANOVA P = 0.001) [ Fig. 2(c) ]. Because the decrease in secreted ACTH occurred before significant apoptosis [ Fig. 2(a) ], we then examined the mechanism by which SAHA may affect ACTH. First, qRT-PCR revealed decreased transcription of POMC with physiologically available concentrations of SAHA. A trend toward decreased POMC expression was seen with lower doses of SAHA (65% 6 0.1% for both 0.5 and 1 mM) [ Fig. 2(d) ]. At a 4-mM dose of SAHA, a significant decrease in expression was confirmed (33% 6 0.07%; ANOVA P = 0.02) [ Fig. 2(d) ]. Suppression of POMC promoter (8) with SAHA (1 mM at 3 hours) with a POMC promoter luciferase transfection study was corroborated [ Fig. 2(e) ].
SAHA reduced human tumor survival and ACTH secretion ex vivo
Human tumors causing CD are genetically heterogeneous (22) . Therefore, we confirmed the effect of SAHA on hCtTs derived from surgical extirpation in eight patients with CD (8) . SAHA (1 mM; 24 hours) decreased hCtT survival (78.92%; P = 0.0007) [ Fig. 1(f) ] and ACTH secretion (83.64%; P = 0.03) [ Fig. 2(f) ]. Following Sanger sequencing (Supplemental Materials and Methods), we identified two adenomas with the same USP8 gene mutation (p.Arg715Gly) within the previously reported hot spot (22) . These adenomatous cells behaved similarly to wild-type cells in vitro.
SAHA had pleiotropic effects on gene expression in AtT-20 cells
To characterize the changes in gene expression exerted by HDACi exposure, AtT-20 cells were treated with SAHA (1 mM), valproic acid (4 mM), and panobinostat (200 nM) for 3 hours and subsequently investigated by whole-genome microarray analysis. With SAHA Fig. 3(a) ]. Functional analysis of statistically significant DEGs revealed the effects of SAHA in two relevant clusters, graphically represented in a heatmap [ Fig. 3(c) ]. First, a cluster of closely correlated genes (EASE score = 0.47) of zinc finger nuclear receptors (Nr1d2, Nr1h3, Nr2f1, and Nr2f2) was downregulated. From our list of DEGs, SAHA induced a 2.3-fold downregulation of the nuclear receptor subfamily 1 group H member 3 (Nr1h3) gene, also known as LXRa (P = 0.027) (23) . Notably, a direct correlation (confidence score = 0.706) was found between POMC and LXRa in the STRING database. In the second pathway, genes of the mitochondria-mediated death pathway (Bid, Dffa, Casp6, Casp9) were upregulated (EASE score = 0.67). A robust increase in expression of the BH3-interacting domain death agonist (Bid) gene was noted (2.7-fold; P = 0.02). Lastly, to understand the global interactions among DEGs, the Kyoto Encyclopedia of Genes and Genomes was used. Correspondingly, 34 pathways were affected following SAHA exposure [ Fig. 3(b) ].
SAHA downregulated LXRa expression in AtT-20 cells but not in normal corticotrophs
Because a direct association was discovered between POMC and LXRa in the STRING database, we proceeded to examine the effects of SAHA on LXRa and its obligate heterodimer, RXRa. When AtT-20 cells were exposed to increasing concentrations of SAHA (0.5 to 8 mM) for 3 hours, LXRa protein expression was reduced in a dose-dependent fashion, as indicated by immunoblot and densitometric analyses [ Fig. 4(a) ]. qRT-PCR demonstrated concomitantly reduced LXRa messenger RNA (mRNA) levels [ Fig. 4(b) ]. RXRa protein expression, however, was not altered by SAHA [ Fig. 4(a) ]. Expectedly, RXRa mRNA was insignificantly reduced with SAHA exposure (.0.5-fold for all SAHA concentrations tested) [ Fig. 4(b) ]. In addition, quantification of LXRa/RXRa heterodimers was performed with protein-complex . In addition, serum ACTH levels were assessed to corroborate the effects of SAHA on hormonal hypersecretion seen in vitro. ACTH levels drastically decreased in mice harboring tumors treated with either SAHA 25 or 50 mg/kg vs tumor mice that received only saline (P , 0.0001) [ Fig. 5(c) ].
Reduction in plasma ACTH level can be attributed to tumor involution; therefore, we tested the early effects of SAHA on serum ACTH levels in control mice. SAHA, valproate, or panobinostat had no effects on basal serum ACTH levels at 3 hours in healthy nude-mice, confirming the selectivity of HDACi toward tumor cells observed in vitro (Supplemental Fig. 1B) .
We then evaluated the effect of 5-day SAHA treatment on chronic effects of excess ACTH in the flank tumor model. The increased adrenal gland weight seen in tumor groups did not change significantly among treatment groups [ Fig. 5(d) ]. Similarly, reversal of skin thinning in tumor-implanted animals was nonstatistically significant with SAHA treatment [ Fig. 5 (e) and 5(f)].
Discussion
Most effective pharmacological treatments for CD are aimed at the endocrine organs but come with major adverse effects (4) . The ones targeting the pituitary gland, such as dopamine agonists, have been largely ineffective, requiring lifelong administration and poor rates of compliance (6) . Tumor-targeting therapies, including retinoic acid (8, 9), unfortunately did not perform well in the clinical setting (10) . Previous evidence demonstrated that the antiproliferative effects of retinoic acid were hindered in AtT-20 cells expressing chicken ovalbumin upstream promoter transcription factor 1 (COUP-TF1) (8) . Immunohistochemistry demonstrated the ubiquitous expression of COUP-TF1 in normal human corticotroph cells, suggesting an underlying mechanism of resistance for normal cells (8) . ACTH-secreting cell lines are heterogeneous, and we found that in the AtT-20/D16/16 cell line, COUP-TF1 was abundantly expressed (Supplemental Fig. 1D ), making this an unlikely target for retinoic acid. Unlike retinoic acid, SAHA appears to overcome COUP-TF12mediated resistance in AtT-20 cells.
Acetylation of the nucleosomal core histones regulates numerous biological processes, including cell cycle regulation, cellular proliferation, and apoptosis, suggesting a potential role in regulating tumor progression (25) . In this study, we corroborated the antiproliferative effect of the FDA-approved pan-HDACi SAHA in the corticotroph adenoma cell line AtT-20/D16/16 and subsequently confirmed this in hCtT cells. Explicitly, clinically achievable doses of SAHA reduced the viability of AtT-20 in concentration-and time-dependent manners following 3-to 72-hour treatment, as evaluated by MTT assay [ Fig. 1(a) ]. SAHA increased proteolysis of PARP, a hallmark of apoptotic cell death catalyzed by the activation of caspase-3 (26), along with an increase in the Bax/Bcl2 ratio consistent with a proapoptotic effect and in agreement with previous evidence [ Fig. 1(d) and 1(e)] (13).
SAHA can trigger apoptosis via the mitochondrial/ intrinsic (27) and death receptor/extrinsic pathways (27) . Furthermore, SAHA may trigger mitochondrialmediated death through increased activity and/or expression of proapoptotic genes such as Bid, Bim, Bmf, Puma, and Noxa (28). In agreement, our large-scale gene expression analysis substantiated activation of the mitochondrial death pathway via Bid upregulation. Translocation of cleaved Bid to the mitochondria triggered cytochrome c release and consequently initiated the apoptotic program (29) . Although ACTH-producing adenomas are characterized by a relatively slow rate of growth compared with that of other malignant brain tumors, a chronic state of hypercortisolism contributes to high patient morbidity. Our study demonstrated that within 3 hours of exposure, SAHA decreased levels of ACTH secretion by AtT-20 cells, with the effect being maintained at the 24-hour mark [ Fig. 2(b) and 2(c) ]. This was confirmed ex vivo, where ACTH reduction by 20% after 24 hours from CtT adenoma cells in humans was observed [ Fig. 2(f) ]. Furthermore, in vivo testing using a xenograph model led to ACTH reduction in mice treated with SAHA [ Fig. 5(c) ]. These early effects of SAHA may be due to significant downregulation of POMC expression, as demonstrated by qRT-PCR [ Fig. 2(d) ], and suppression of the POMC promoter, as seen in the luciferase transfection study, leading in turn to a reduction in ACTH release [ Fig. 2(e) ]. These results compare favorably with the effects of pasireotide in the reduction of ACTH secretion (approximately 10% at 24 hours) (30) .
Whole-genome analysis revealed that SAHA induced a 2.3-fold downregulation of the LXRa gene. Using the STRING database to assess functional protein association networks, we identified a direct correlation between POMC and LXRa. LXRa and b are ligand-activated transcription factors belonging to the nuclear receptor superfamily (23) , for which activity is dependent on the formation of obligate heterodimers with the RXRs (23). In the absence of ligand activation, the RXR/LXR heterodimer is thought to remain bound to the promoter region in complex with corepressors, thereby blocking the activation of target genes (23) . LXRs play a critical role in the control of gene transcription involved in lipid and carbohydrate metabolism (23, 31, 32) . Moreover, recent studies have shed light on the possible roles of LXRs in the hypothalamic-pituitary-adrenal axis, where the use of a synthetic LXR ligand (TO901317) induced POMC gene expression in mice pituitary glands via binding of LXRa to the LXR response element 1 found within the promoter region of POMC (Fig. 6) (33) . This suggests that LXRa positively regulates the POMC gene at the transcriptional level.
Interestingly, in our study, SAHA reduced both the protein and mRNA levels of LXRa but did not seem to have a significant effect on RXRa [ Fig. 4(f) ]. Expectedly, immunoprecipitation showed that LXRa/RXRa heterodimerization was reduced with increasing doses of SAHA, in part because of reduced LXRa availability [ Fig. 4(c) ]. Our work provides evidence that SAHA suppressed expression of the prohormone POMC, abolishing ACTH hypersecretion. LXRa degradation seems to be the predominant mechanism for this response, though the details remain to be elucidated (Fig. 6) .
Consistent with previous studies validating the beneficial effects of SAHA on malignant cell lines (34, 35) , clinically relevant concentrations were effective in abrogating tumor growth in a nude-mice AtT-20 xenograft model, and tumor volume was suppressed up to 70% In humans, CD is caused by adenomas that are quite heterogeneous, both in terms of underlying genetic mutations (22) and gene expressions. We found that SAHA was also effective against hCtT (n = 7) [ Fig. 1(e) and 1(f) ]. A clinical trial is planned to evaluate the effects of SAHA on ACTH and cortisol levels in addition to the expected antitumor effect. HDACis are also effective radiosensitizers (37, 38) , raising the possibility of coadjuvant SAHA and radiation for recurrent CD. Lastly, epidermal growth factor receptor signaling is affected by USP8 mutation (22) and may in turn lead to POMC upregulation (39) . SAHA may affect epidermal growth factor receptor signaling through its effects on cytoplasmic HDAC6 (40) .
Conclusion
In this study, the proapoptotic effect of the FDAapproved HDACi SAHA in ACTH-secreting cells was observed. Decreased cellular viability and elevated markers of proapoptotic cell death were demonstrated. In vivo testing revealed tumor involution and decreased ACTH levels in an AtT-20 xenograft model. These findings provide evidence of the mechanisms by which SAHA leads to decreased ACTH secretion and support its potential role in the treatment of CD.
